Mona Sabharwal

458 total citations
14 papers, 303 citations indexed

About

Mona Sabharwal is a scholar working on Economics and Econometrics, General Health Professions and Oncology. According to data from OpenAlex, Mona Sabharwal has authored 14 papers receiving a total of 303 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Economics and Econometrics, 2 papers in General Health Professions and 2 papers in Oncology. Recurrent topics in Mona Sabharwal's work include Health Systems, Economic Evaluations, Quality of Life (10 papers), Economic and Financial Impacts of Cancer (9 papers) and Pharmaceutical Economics and Policy (3 papers). Mona Sabharwal is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (10 papers), Economic and Financial Impacts of Cancer (9 papers) and Pharmaceutical Economics and Policy (3 papers). Mona Sabharwal collaborates with scholars based in Canada, United Kingdom and United States. Mona Sabharwal's co-authors include Jeffrey S. Hoch, Olavo Fernandes, Gideon Koren, Thomas R. Einarson, Tom Smiley, Anne Pastuszak, Kelvin Chan, Matthew C. Cheung, Gerald A. Evans and Janet Martin and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Social Science & Medicine.

In The Last Decade

Mona Sabharwal

14 papers receiving 293 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mona Sabharwal Canada	9	145	57	51	46	43	14	303
PC Hannaford United Kingdom	7	74 0.5×	102 1.8×	54 1.1×	103 2.2×	16 0.4×	7	450
V. Foos United Kingdom	14	207 1.4×	17 0.3×	37 0.7×	78 1.7×	41 1.0×	50	1.1k
Ulrike Lampert Germany	6	67 0.5×	152 2.7×	23 0.5×	15 0.3×	59 1.4×	10	301
Gisbert Selke Germany	10	202 1.4×	19 0.3×	30 0.6×	68 1.5×	46 1.1×	20	765
Prescott United Kingdom	6	91 0.6×	171 3.0×	19 0.4×	27 0.6×	90 2.1×	9	374
Narcyz Ghinea Australia	9	116 0.8×	54 0.9×	16 0.3×	36 0.8×	45 1.0×	48	249
Anna Hung United States	10	82 0.6×	30 0.5×	19 0.4×	17 0.4×	38 0.9×	58	292
Laurence Lagarce France	11	25 0.2×	87 1.5×	16 0.3×	58 1.3×	11 0.3×	28	296
Jill Bates United States	11	34 0.2×	75 1.3×	27 0.5×	43 0.9×	52 1.2×	30	363
Ye Zhu United States	10	36 0.2×	43 0.8×	22 0.4×	52 1.1×	17 0.4×	22	276

Countries citing papers authored by Mona Sabharwal

Since Specialization

Citations

This map shows the geographic impact of Mona Sabharwal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mona Sabharwal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mona Sabharwal more than expected).

Fields of papers citing papers by Mona Sabharwal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mona Sabharwal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mona Sabharwal. The network helps show where Mona Sabharwal may publish in the future.

Co-authorship network of co-authors of Mona Sabharwal

This figure shows the co-authorship network connecting the top 25 collaborators of Mona Sabharwal. A scholar is included among the top collaborators of Mona Sabharwal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mona Sabharwal. Mona Sabharwal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Truong, Judy, et al.. (2019). The impact of pricing strategy on the costs of oral anti‐cancer drugs. Cancer Medicine. 8(8). 3770–3781. 8 indexed citations

Srikanthan, Amirrtha, Natasha Penner, Kelvin Chan, Mona Sabharwal, & Allan Grill. (2018). Understanding the Reasons for Provincial Discordance in Cancer drug Funding—A Survey of Policymakers. Current Oncology. 25(4). 257–261. 6 indexed citations

Truong, Judy, et al.. (2017). The impact of cancer drug wastage on economic evaluations. Cancer. 123(18). 3583–3590. 10 indexed citations

Masucci, Lisa, Jaclyn Beca, Mona Sabharwal, & Jeffrey S. Hoch. (2017). Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR). PharmacoEconomics - Open. 1(4). 255–263. 16 indexed citations

Srikanthan, Amirrtha, Natasha Penner, Eitan Amir, et al.. (2017). Impact of the Pan-Canadian Oncology Drug Review on Provincial Concordance with Respect to Cancer Drug Funding Decisions and Time to Funding. Current Oncology. 24(5). 295–301. 7 indexed citations

Cheng, Sierra, Matthew C. Cheung, Di Jiang, et al.. (2017). Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?. Journal of Clinical Oncology. 35(24). 2764–2771. 42 indexed citations

Cheng, Sierra, Matthew C. Cheung, Di Jiang, et al.. (2017). Do the American Society of Clinical Oncology (ASCO) Value Framework and the European Society of Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale measure the same construct of clinical benefit?. Journal of Clinical Oncology. 35(15_suppl). 6509–6509. 2 indexed citations

Cheung, Matthew C., et al.. (2016). Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences?. ESMO Open. 1(6). e000124–e000124. 6 indexed citations

Regier, Dean A., Colene Bentley, Craig Mitton, et al.. (2014). Public engagement in priority-setting: Results from a pan-Canadian survey of decision-makers in cancer control. Social Science & Medicine. 122. 130–139. 19 indexed citations

10.

Hoch, Jeffrey S. & Mona Sabharwal. (2013). Informing Canada’s Cancer Drug Funding Decisions with Scientific Evidence and Patient Perspectives: The Pan-Canadian Oncology Drug Review. Current Oncology. 20(2). 121–124. 26 indexed citations

11.

Winquist, Eric, Chaim M. Bell, Joe T.R. Clarke, et al.. (2012). An Evaluation Framework for Funding Drugs for Rare Diseases. Value in Health. 15(6). 982–986. 41 indexed citations

12.

Bell, Chaim M., et al.. (2009). PHP31 A POLICY FRAMEWORK FOR FUNDING DRUGS FOR RARE DISEASES. Value in Health. 12(7). A243–A243. 1 indexed citations

13.

Dolovich, Lisa, et al.. (2007). The effect of pharmacist education on asthma treatment plans for simulated patients. Pharmacy World & Science. 29(3). 228–239. 31 indexed citations

14.

Fernandes, Olavo, Mona Sabharwal, Tom Smiley, et al.. (1998). Moderate to heavy caffeine consumption during pregnancy and relationship to spontaneous abortion and abnormal fetal growth: a meta-analysis. Reproductive Toxicology. 12(4). 435–444. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact